Trial · NCT01227928
Results by group228
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 228
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Progression-free Survival (PFS) | Placebo | 18.1 | 95% Confidence Interval 12.1 to NA | months | |
| Progression-free Survival (PFS) | Pazopanib 800 Milligrams | 18.1 | 95% Confidence Interval 18.0 to 18.1 | months | |
| Overall Survival | Placebo | NA | 95% Confidence Interval NA to NA | months | |
| Overall Survival | Pazopanib 800 Milligrams | NA | 95% Confidence Interval NA to NA | months | |
| PFS by Gynaecologic Cancer Intergroup (GCIG) Criteria | Placebo | 15.2 | 95% Confidence Interval 9.0 to NA | months | |
| PFS by Gynaecologic Cancer Intergroup (GCIG) Criteria | Pazopanib 800 Milligrams | 16.1 | 95% Confidence Interval 14.2 to 18.2 | months | |
| Number of Participants With Any Dose Reduction or Any Dose Interruption | Placebo | Any Reduction | 26 | participants | |
| Number of Participants With Any Dose Reduction or Any Dose Interruption | Pazopanib 800 Milligrams | Any Reduction | 64 | participants | |
| Number of Participants With Any Dose Reduction or Any Dose Interruption | Placebo | Any Interruption | 44 | participants | |
| Number of Participants With Any Dose Reduction or Any Dose Interruption | Pazopanib 800 Milligrams | Any Interruption | 65 | participants | |
| Number of Participants With Any Non-serious Adverse Event (AE) and Any Serious Adverse Event (SAE) | Placebo | Any AE | 65 | participants | |
| Number of Participants With Any Non-serious Adverse Event (AE) and Any Serious Adverse Event (SAE) | Pazopanib 800 Milligrams | Any AE | 72 | participants | |
| Number of Participants With Any Non-serious Adverse Event (AE) and Any Serious Adverse Event (SAE) | Placebo | Any SAE | 4 | participants | |
| Number of Participants With Any Non-serious Adverse Event (AE) and Any Serious Adverse Event (SAE) | Pazopanib 800 Milligrams | Any SAE | 7 | participants | |
| Number of Participants With Any On-therapy AE and Any AE Related to Study Treatment | Placebo | Any on-therapy AE | 65 | participants | |
| Number of Participants With Any On-therapy AE and Any AE Related to Study Treatment | Pazopanib 800 Milligrams | Any on-therapy AE | 72 | participants | |
| Number of Participants With Any On-therapy AE and Any AE Related to Study Treatment | Placebo | Any AE related to study treatment | 52 | participants | |
| Number of Participants With Any On-therapy AE and Any AE Related to Study Treatment | Pazopanib 800 Milligrams | Any AE related to study treatment | 71 | participants | |
| Number of Participants With Any Grade 3 or 4 AE | Placebo | 8 | participants | ||
| Number of Participants With Any Grade 3 or 4 AE | Pazopanib 800 Milligrams | 39 | participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01227928/results